<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000822'>Hypertension</z:hpo> (HT) and <z:hpo ids='HP_0000726'>dementia</z:hpo> are common disorders in the elderly </plain></SENT>
<SENT sid="1" pm="."><plain>HT in the elderly is associated with increased occurrence rates of <z:hpo ids='HP_0000726'>dementia</z:hpo> including <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) </plain></SENT>
<SENT sid="2" pm="."><plain>In connection to this, some studies have suggested that HT in old age correlates with the pathogenesis of <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Since HT is potentially reversible, a number of randomized trials have examined whether <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> treatment may help in preventing <z:hpo ids='HP_0000726'>dementia</z:hpo> occurrence </plain></SENT>
<SENT sid="4" pm="."><plain>We review five studies, <z:hpo ids='HP_0000001'>all</z:hpo> using subjects 60 years or older, which investigated different <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> pharmacological treatments </plain></SENT>
<SENT sid="5" pm="."><plain>Data from two trials (Syst-Eur, PROGRESS) open the way toward the prevention of <z:hpo ids='HP_0000726'>dementia</z:hpo> (AD or VaD) by <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> treatments </plain></SENT>
<SENT sid="6" pm="."><plain>In the Syst-Eur study, with the <z:chebi fb="0" ids="50075">dihydropyridine</z:chebi> calcium <z:chebi fb="68" ids="48706">antagonists</z:chebi>, a reduction in both types of <z:hpo ids='HP_0000726'>dementia</z:hpo> was demonstrated (risk reduction 55%) </plain></SENT>
<SENT sid="7" pm="."><plain>The PROGRESS study showed that the use of <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitors</z:chebi> (ACEIs), with or without <z:chebi fb="40" ids="35498">diuretics</z:chebi>, resulted in decrease incidence of <z:hpo ids='HP_0001297'>stroke</z:hpo>-related <z:hpo ids='HP_0000726'>dementia</z:hpo> (risk reduction 19%), but <z:hpo ids='HP_0000726'>dementia</z:hpo> without <z:hpo ids='HP_0001297'>stroke</z:hpo> was not reduced </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, the SHEP trial, treatment with a <z:chebi fb="0" ids="3654">chlorthalidone</z:chebi>-based <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> regimen, did not significantly reduced the incidence of <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>The SCOPE study (<z:chebi fb="0" ids="3347">candesartan</z:chebi> or hydrochlorothiazide versus placebo) and the HYVET-COG study (indapamide or <z:chebi fb="0" ids="8024">perindopril</z:chebi> versus placebo) found no significant difference between the active treatment and placebo group on the incidence of <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>We found conflicting results regarding treatment benefits in <z:hpo ids='HP_0000726'>dementia</z:hpo> prevention </plain></SENT>
<SENT sid="11" pm="."><plain>Recent clinical trials and studies on animal models suggest that blockades of <z:mp ids='MP_0011356'>RAS</z:mp> system could have reduced <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> seen in <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Future trials primarily designed to investigate the effects of <z:chebi fb="0" ids="35674">antihypertensive agents</z:chebi> on <z:e sem="disease" ids="C0338656" disease_type="Mental or Behavioral Dysfunction" abbrv="">impaired cognition</z:e> are needed </plain></SENT>
</text></document>